Clinical Trial Finder

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Study Purpose

This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Documentation of disease.
  • - Histologic documentation: Histologically-proven advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma.
  • - Stage: Advanced (metastatic or unresectable primary) disease.
  • - Tumor site: Histologically-proven pheochromocytoma or paraganglioma.
  • - Radiographic evaluation: Radiographic evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in the 12 months prior to registration.
  • - Measurable disease.
  • - Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes).
Non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung.
  • - Prior treatment with other somatostatin analog, chemotherapy, radiotherapy (including peptide radionuclide receptor therapy [PRRT]), or surgery must be completed >= 28 days prior to registration.
Patients must have recovered from any effects of any major surgery prior to registration.
  • - Prior treatment with radiolabeled metaiodobenzylguanidine (MIBG) must be completed >= 12 weeks prior to registration and lifetime cumulative 131I-MIBG dose must be < 1000 MBq kg^-1 (36 mCi kg^-1) - Prior treatment with antibiotics must be completed >= 7 days prior to registration.
  • - No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor.
  • - No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUCBT) - Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects.
Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required.
  • - Contraception.
  • - Therapy utilized in this trial is associated with medium/high fetal risk.
  • - Women of childbearing potential and their partners, who are sexually active, must agree to use two highly effective forms of contraception in combination.
This should be started from the time of registration and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse.
  • - Male patients must use a condom during treatment and for 3 months after the last dose of study drug(s) when having sexual intercourse with a pregnant woman or with a woman of childbearing potential.
Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking study drug(s) and for 3 months following the last dose of study drug(s)
  • - Age >= 18 years.
  • - Eastern Cooperative Oncology Group (ECOG) performance status: 0-2.
  • - Absolute neutrophil count >= 1,500/mm^3.
  • - Platelet count >= 100,000/mm^3.
  • - Hemoglobin >= 10 mg/dL if prior radionuclide therapy Hemoglobin >= 8 mg/dL if no prior radionuclide therapy.
  • - In the absence of transfusion within the previous 24 hours.
Radionuclide therapy includes PRRT or MIBG.
  • - Total bilirubin =< 1.5 x upper limit of normal (ULN) - Except in the case of Gilbert's syndrome, then total bilirubin must be =< 3.0 x ULN.
  • - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN.
  • - Creatinine < 1.5 x ULN OR calculated (calc.
) creatinine clearance > 50 mL/min.
  • - Calculated by Cockcroft-Gault equation.
  • - No indication of uncontrolled, potentially reversible cardiac condition(s) as determined by investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's formula-corrected QT interval [QTcF] prolongation > 500 msec, electrolyte disturbances, etc.) and no known congenital long QT syndrome.
  • - No extensive bilateral lung disease or pneumonitis.
  • - No abnormal organ or bone marrow function =< 28 days prior to registration.
  • - Patients with human immunodeficiency virus (HIV) positivity are allowed if CD4 count > 250 cells/uL and they have an undetectable HIV viral load within 6 months of registration.
  • - No active infection.
  • - No history of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia.
  • - No known gastrointestinal condition(s) that might predispose for drug intolerability or poor drug absorption.
  • - No known medical condition causing an inability to swallow oral formulations of agents.
  • - No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PARP inhibitors.
  • - Concurrent use of combination antiretroviral therapy (ART) is not permitted.
  • - Chronic concomitant treatment with strong or moderate CYP3A4 inducers or inhibitors is not allowed.
Patients must discontinue the agent(s) >= 21 days prior to registration; enzalutamide and/or phenobarbital must be discontinued >= 5 weeks prior to registration

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT04394858
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 National Cancer Institute (NCI)
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 Jaydira Del Rivero
Principal Investigator Affiliation Alliance for Clinical Trials in Oncology
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 NIH
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
Additional Details

PRIMARY OBJECTIVE:

  • I. To compare the progression-free survival (PFS) of patients with advanced pheochromocytoma and paraganglioma (APP) receiving temozolomide (dose dense) and olaparib to that of patients receiving temozolomide (pulse dose) alone.
SECONDARY OBJECTIVES:
  • I. To compare the overall survival (OS) of patients with APP receiving temozolomide (dose dense) and olaparib versus (vs.#46;) temozolomide (pulse dose) alone.
  • II. To compare the objective response rate (ORR) associated with temozolomide (dose dense) and olaparib vs.#46; temozolomide (pulse dose) alone in patients with APP.
  • III. To evaluate and compare the toxicity profile of temozolomide-based combinations (temozolomide [dose dense] and olaparib vs.#46; temozolomide [pulse dose]) in patients with APP using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE.
OTHER OBJECTIVE:
  • I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
EXPLORATORY OBJECTIVES:
  • I. To assess biochemical response: serum catecholamines and metanephrines; urine catecholamines and metanephrines.
  • II. To assess biomolecular markers associated with clinical outcome: germline succinyl dehydrogenase (SDH) mutations and tumor status of the repair enzyme methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT).
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive temozolomide orally (PO) once daily (QD) and olaparib PO twice daily (BID) on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with contrast or magnetic resonance imaging (MRI) throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. ARM II: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. Patients discontinuing treatment due to reasons other than disease progression are followed every 8 weeks until disease progression, then every 6 months until 5 years after start of treatment. Patients discontinuing treatment due to disease progression are followed every 6 months for 5 years after start of treatment.

Arms & Interventions

Arms

Experimental: Arm I (temozolomide, olaparib)

Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.

Active Comparator: Arm II (temozolomide)

Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.

Interventions

Procedure: - Biospecimen Collection

Undergo collection of blood samples

Procedure: - Computed Tomography with Contrast

Undergo CT with contrast

Procedure: - Magnetic Resonance Imaging

Undergo MRI

Drug: - Olaparib

Given PO

Other: - Quality-of-Life Assessment

Ancillary studies

Drug: - Temozolomide

Given PO

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Anchorage, Alaska

Status

Suspended

Address

Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508

Anchorage Radiation Therapy Center, Anchorage, Alaska

Status

Suspended

Address

Anchorage Radiation Therapy Center

Anchorage, Alaska, 99504

Alaska Breast Care and Surgery LLC, Anchorage, Alaska

Status

Suspended

Address

Alaska Breast Care and Surgery LLC

Anchorage, Alaska, 99508

Alaska Oncology and Hematology LLC, Anchorage, Alaska

Status

Suspended

Address

Alaska Oncology and Hematology LLC

Anchorage, Alaska, 99508

Alaska Women's Cancer Care, Anchorage, Alaska

Status

Suspended

Address

Alaska Women's Cancer Care

Anchorage, Alaska, 99508

Anchorage Oncology Centre, Anchorage, Alaska

Status

Suspended

Address

Anchorage Oncology Centre

Anchorage, Alaska, 99508

Katmai Oncology Group, Anchorage, Alaska

Status

Suspended

Address

Katmai Oncology Group

Anchorage, Alaska, 99508

Providence Alaska Medical Center, Anchorage, Alaska

Status

Suspended

Address

Providence Alaska Medical Center

Anchorage, Alaska, 99508

Burbank, California

Status

Suspended

Address

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank, California, 91505

Holy Cross Hospital, Fort Lauderdale, Florida

Status

Suspended

Address

Holy Cross Hospital

Fort Lauderdale, Florida, 33308

Mayo Clinic in Florida, Jacksonville, Florida

Status

Withdrawn

Address

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Status

Suspended

Address

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

Fruitland, Idaho

Status

Suspended

Address

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Status

Suspended

Address

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Status

Suspended

Address

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83686

Twin Falls, Idaho

Status

Suspended

Address

Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301

Illinois CancerCare-Bloomington, Bloomington, Illinois

Status

Recruiting

Address

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Canton, Canton, Illinois

Status

Recruiting

Address

Illinois CancerCare-Canton

Canton, Illinois, 61520

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Carthage, Carthage, Illinois

Status

Recruiting

Address

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Centralia Oncology Clinic, Centralia, Illinois

Status

Recruiting

Address

Centralia Oncology Clinic

Centralia, Illinois, 62801

Site Contact

Site Public Contact

morganthaler.jodi@mhsil.com

217-876-4762

Chicago, Illinois

Status

Recruiting

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Site Contact

Site Public Contact

cancerclinicaltrials@bsd.uchicago.edu

773-702-8222

Carle at The Riverfront, Danville, Illinois

Status

Recruiting

Address

Carle at The Riverfront

Danville, Illinois, 61832

Site Contact

Site Public Contact

Research@Carle.com

800-446-5532

Decatur, Illinois

Status

Recruiting

Address

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Site Contact

Site Public Contact

morganthaler.jodi@mhsil.com

217-876-4762

Illinois CancerCare-Dixon, Dixon, Illinois

Status

Recruiting

Address

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

Site Contact

Site Public Contact

815-285-7800

Carle Physician Group-Effingham, Effingham, Illinois

Status

Recruiting

Address

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Site Contact

Site Public Contact

Research@carle.com

800-446-5532

Crossroads Cancer Center, Effingham, Illinois

Status

Recruiting

Address

Crossroads Cancer Center

Effingham, Illinois, 62401

Site Contact

Site Public Contact

morganthaler.jodi@mhsil.com

217-876-4762

Illinois CancerCare-Eureka, Eureka, Illinois

Status

Recruiting

Address

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Galesburg, Galesburg, Illinois

Status

Recruiting

Address

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois

Status

Recruiting

Address

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Macomb, Macomb, Illinois

Status

Recruiting

Address

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

Status

Recruiting

Address

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Site Contact

Site Public Contact

Research@carle.com

800-446-5532

New Lenox, Illinois

Status

Recruiting

Address

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Site Contact

Site Public Contact

cancerclinicaltrials@bsd.uchicago.edu

773-702-8222

Cancer Care Center of O'Fallon, O'Fallon, Illinois

Status

Recruiting

Address

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Site Contact

Site Public Contact

morganthaler.jodi@mhsil.com

217-876-4762

Orland Park, Illinois

Status

Recruiting

Address

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Site Contact

Site Public Contact

cancerclinicaltrials@bsd.uchicago.edu

773-702-8222

Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois

Status

Recruiting

Address

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Pekin, Pekin, Illinois

Status

Recruiting

Address

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Peoria, Peoria, Illinois

Status

Recruiting

Address

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Peru, Peru, Illinois

Status

Recruiting

Address

Illinois CancerCare-Peru

Peru, Illinois, 61354

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Illinois CancerCare-Princeton, Princeton, Illinois

Status

Recruiting

Address

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Carle Cancer Center, Urbana, Illinois

Status

Recruiting

Address

Carle Cancer Center

Urbana, Illinois, 61801

Site Contact

Site Public Contact

Research@carle.com

800-446-5532

Illinois CancerCare - Washington, Washington, Illinois

Status

Recruiting

Address

Illinois CancerCare - Washington

Washington, Illinois, 61571

Site Contact

Site Public Contact

andersonj@illinoiscancercare.com

309-243-3605

Bethesda, Maryland

Status

Recruiting

Address

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892

Site Contact

Site Public Contact

800-411-1222

Dana-Farber Cancer Institute, Boston, Massachusetts

Status

Recruiting

Address

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

Site Contact

Site Public Contact

877-442-3324

Newton, Massachusetts

Status

Suspended

Address

Dana-Farber Cancer Institute - Chestnut Hill

Newton, Massachusetts, 02467

Saint Joseph Mercy Hospital, Ann Arbor, Michigan

Status

Recruiting

Address

Saint Joseph Mercy Hospital

Ann Arbor, Michigan, 48106

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Saint Joseph Mercy Brighton, Brighton, Michigan

Status

Recruiting

Address

Saint Joseph Mercy Brighton

Brighton, Michigan, 48114

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Brighton, Michigan

Status

Recruiting

Address

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Saint Joseph Mercy Canton, Canton, Michigan

Status

Recruiting

Address

Saint Joseph Mercy Canton

Canton, Michigan, 48188

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Canton, Michigan

Status

Recruiting

Address

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Caro Cancer Center, Caro, Michigan

Status

Suspended

Address

Caro Cancer Center

Caro, Michigan, 48723

Saint Joseph Mercy Chelsea, Chelsea, Michigan

Status

Recruiting

Address

Saint Joseph Mercy Chelsea

Chelsea, Michigan, 48118

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Chelsea, Michigan

Status

Recruiting

Address

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Clarkston, Michigan

Status

Recruiting

Address

Hematology Oncology Consultants-Clarkston

Clarkston, Michigan, 48346

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Newland Medical Associates-Clarkston, Clarkston, Michigan

Status

Recruiting

Address

Newland Medical Associates-Clarkston

Clarkston, Michigan, 48346

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Ascension Saint John Hospital, Detroit, Michigan

Status

Recruiting

Address

Ascension Saint John Hospital

Detroit, Michigan, 48236

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

East China Township, Michigan

Status

Recruiting

Address

Great Lakes Cancer Management Specialists-Doctors Park

East China Township, Michigan, 48054

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

Flint, Michigan

Status

Recruiting

Address

Genesee Cancer and Blood Disease Treatment Center

Flint, Michigan, 48503

Site Contact

Site Public Contact

wstrong@ghci.org

810-762-8038

Genesee Hematology Oncology PC, Flint, Michigan

Status

Recruiting

Address

Genesee Hematology Oncology PC

Flint, Michigan, 48503

Site Contact

Site Public Contact

wstrong@ghci.org

810-762-8038

Genesys Hurley Cancer Institute, Flint, Michigan

Status

Recruiting

Address

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Site Contact

Site Public Contact

wstrong@ghci.org

810-762-8038

Hurley Medical Center, Flint, Michigan

Status

Recruiting

Address

Hurley Medical Center

Flint, Michigan, 48503

Site Contact

Site Public Contact

wstrong@ghci.org

810-762-8038

Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan

Status

Recruiting

Address

Academic Hematology Oncology Specialists

Grosse Pointe Woods, Michigan, 48236

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

Grosse Pointe Woods, Michigan

Status

Recruiting

Address

Great Lakes Cancer Management Specialists-Van Elslander Cancer Center

Grosse Pointe Woods, Michigan, 48236

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

Grosse Pointe Woods, Michigan

Status

Suspended

Address

Michigan Breast Specialists-Grosse Pointe Woods

Grosse Pointe Woods, Michigan, 48236

Lansing, Michigan

Status

Suspended

Address

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Hope Cancer Clinic, Livonia, Michigan

Status

Suspended

Address

Hope Cancer Clinic

Livonia, Michigan, 48154

Livonia, Michigan

Status

Recruiting

Address

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Macomb, Michigan

Status

Recruiting

Address

Great Lakes Cancer Management Specialists-Macomb Medical Campus

Macomb, Michigan, 48044

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

Macomb, Michigan

Status

Suspended

Address

Michigan Breast Specialists-Macomb Township

Macomb, Michigan, 48044

Marlette, Michigan

Status

Suspended

Address

Saint Mary's Oncology/Hematology Associates of Marlette

Marlette, Michigan, 48453

21st Century Oncology-Pontiac, Pontiac, Michigan

Status

Recruiting

Address

21st Century Oncology-Pontiac

Pontiac, Michigan, 48341

Site Contact

Site Public Contact

Emily.Crofts@trinity-health.org

248-858-6215

Hope Cancer Center, Pontiac, Michigan

Status

Suspended

Address

Hope Cancer Center

Pontiac, Michigan, 48341

Newland Medical Associates-Pontiac, Pontiac, Michigan

Status

Recruiting

Address

Newland Medical Associates-Pontiac

Pontiac, Michigan, 48341

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Saint Joseph Mercy Oakland, Pontiac, Michigan

Status

Recruiting

Address

Saint Joseph Mercy Oakland

Pontiac, Michigan, 48341

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Rochester Hills, Michigan

Status

Suspended

Address

Great Lakes Cancer Management Specialists-Rochester Hills

Rochester Hills, Michigan, 48309

Ascension Saint Mary's Hospital, Saginaw, Michigan

Status

Recruiting

Address

Ascension Saint Mary's Hospital

Saginaw, Michigan, 48601

Site Contact

Site Public Contact

lori.srebinski@ascension.org

989-907-8411

Saginaw, Michigan

Status

Recruiting

Address

Oncology Hematology Associates of Saginaw Valley PC

Saginaw, Michigan, 48604

Site Contact

Site Public Contact

lori.srebinski@ascension.org

989-907-8411

Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan

Status

Recruiting

Address

Bhadresh Nayak MD PC-Sterling Heights

Sterling Heights, Michigan, 48312

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

Ascension Saint Joseph Hospital, Tawas City, Michigan

Status

Recruiting

Address

Ascension Saint Joseph Hospital

Tawas City, Michigan, 48764

Site Contact

Site Public Contact

lori.srebinski@ascension.org

989-907-8411

Advanced Breast Care Center PLLC, Warren, Michigan

Status

Suspended

Address

Advanced Breast Care Center PLLC

Warren, Michigan, 48088

Warren, Michigan

Status

Recruiting

Address

Great Lakes Cancer Management Specialists-Macomb Professional Building

Warren, Michigan, 48093

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

Macomb Hematology Oncology PC, Warren, Michigan

Status

Suspended

Address

Macomb Hematology Oncology PC

Warren, Michigan, 48093

Michigan Breast Specialists-Warren, Warren, Michigan

Status

Suspended

Address

Michigan Breast Specialists-Warren

Warren, Michigan, 48093

Saint John Macomb-Oakland Hospital, Warren, Michigan

Status

Recruiting

Address

Saint John Macomb-Oakland Hospital

Warren, Michigan, 48093

Site Contact

Site Public Contact

karen.forman@ascension.org

313-343-3166

West Branch, Michigan

Status

Suspended

Address

Saint Mary's Oncology/Hematology Associates of West Branch

West Branch, Michigan, 48661

Huron Gastroenterology PC, Ypsilanti, Michigan

Status

Recruiting

Address

Huron Gastroenterology PC

Ypsilanti, Michigan, 48106

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Ypsilanti, Michigan

Status

Recruiting

Address

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Site Contact

Site Public Contact

MCRCwebsitecontactform@stjoeshealth.org

734-712-7251

Fairview Ridges Hospital, Burnsville, Minnesota

Status

Suspended

Address

Fairview Ridges Hospital

Burnsville, Minnesota, 55337

Minnesota Oncology - Burnsville, Burnsville, Minnesota

Status

Suspended

Address

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

Cambridge Medical Center, Cambridge, Minnesota

Status

Suspended

Address

Cambridge Medical Center

Cambridge, Minnesota, 55008

Mercy Hospital, Coon Rapids, Minnesota

Status

Suspended

Address

Mercy Hospital

Coon Rapids, Minnesota, 55433

Fairview Southdale Hospital, Edina, Minnesota

Status

Suspended

Address

Fairview Southdale Hospital

Edina, Minnesota, 55435

Unity Hospital, Fridley, Minnesota

Status

Active, not recruiting

Address

Unity Hospital

Fridley, Minnesota, 55432

Maple Grove, Minnesota

Status

Suspended

Address

Fairview Clinics and Surgery Center Maple Grove

Maple Grove, Minnesota, 55369

Maplewood, Minnesota

Status

Suspended

Address

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

Saint John's Hospital - Healtheast, Maplewood, Minnesota

Status

Suspended

Address

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

Abbott-Northwestern Hospital, Minneapolis, Minnesota

Status

Recruiting

Address

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Site Contact

Site Public Contact

mmcorc@healthpartners.com

952-993-1517

Hennepin County Medical Center, Minneapolis, Minnesota

Status

Suspended

Address

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Health Partners Inc, Minneapolis, Minnesota

Status

Suspended

Address

Health Partners Inc

Minneapolis, Minnesota, 55454

Monticello Cancer Center, Monticello, Minnesota

Status

Suspended

Address

Monticello Cancer Center

Monticello, Minnesota, 55362

New Ulm Medical Center, New Ulm, Minnesota

Status

Suspended

Address

New Ulm Medical Center

New Ulm, Minnesota, 56073

Fairview Northland Medical Center, Princeton, Minnesota

Status

Suspended

Address

Fairview Northland Medical Center

Princeton, Minnesota, 55371

North Memorial Medical Health Center, Robbinsdale, Minnesota

Status

Suspended

Address

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

Mayo Clinic in Rochester, Rochester, Minnesota

Status

Recruiting

Address

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Site Contact

Site Public Contact

855-776-0015

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota

Status

Suspended

Address

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Regions Hospital, Saint Paul, Minnesota

Status

Suspended

Address

Regions Hospital

Saint Paul, Minnesota, 55101

United Hospital, Saint Paul, Minnesota

Status

Suspended

Address

United Hospital

Saint Paul, Minnesota, 55102

Saint Francis Regional Medical Center, Shakopee, Minnesota

Status

Suspended

Address

Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379

Lakeview Hospital, Stillwater, Minnesota

Status

Suspended

Address

Lakeview Hospital

Stillwater, Minnesota, 55082

Ridgeview Medical Center, Waconia, Minnesota

Status

Suspended

Address

Ridgeview Medical Center

Waconia, Minnesota, 55387

Rice Memorial Hospital, Willmar, Minnesota

Status

Suspended

Address

Rice Memorial Hospital

Willmar, Minnesota, 56201

Woodbury, Minnesota

Status

Suspended

Address

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

Fairview Lakes Medical Center, Wyoming, Minnesota

Status

Suspended

Address

Fairview Lakes Medical Center

Wyoming, Minnesota, 55092

Saint Francis Medical Center, Cape Girardeau, Missouri

Status

Recruiting

Address

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Site Contact

Site Public Contact

sfmc@sfmc.net

573-334-2230

Missoula, Montana

Status

Suspended

Address

Saint Patrick Hospital - Community Hospital

Missoula, Montana, 59802

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey

Status

Recruiting

Address

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Site Contact

Site Public Contact

212-639-7592

Memorial Sloan Kettering Monmouth, Middletown, New Jersey

Status

Recruiting

Address

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Site Contact

Site Public Contact

212-639-7592

Memorial Sloan Kettering Bergen, Montvale, New Jersey

Status

Recruiting

Address

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Site Contact

Site Public Contact

212-639-7592

Memorial Sloan Kettering Commack, Commack, New York

Status

Recruiting

Address

Memorial Sloan Kettering Commack

Commack, New York, 11725

Site Contact

Site Public Contact

212-639-7592

Memorial Sloan Kettering Westchester, Harrison, New York

Status

Recruiting

Address

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Site Contact

Site Public Contact

212-639-7592

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Recruiting

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Site Contact

Site Public Contact

212-639-7592

Memorial Sloan Kettering Nassau, Uniondale, New York

Status

Recruiting

Address

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Site Contact

Site Public Contact

212-639-7592

Columbus, Ohio

Status

Recruiting

Address

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Site Contact

Site Public Contact

Jamesline@osumc.edu

800-293-5066

Lawton, Oklahoma

Status

Recruiting

Address

Cancer Centers of Southwest Oklahoma Research

Lawton, Oklahoma, 73505

Site Contact

Site Public Contact

877-231-4440

Oklahoma City, Oklahoma

Status

Recruiting

Address

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Site Contact

Site Public Contact

ou-clinical-trials@ouhsc.edu

405-271-8777

Saint Charles Health System, Bend, Oregon

Status

Suspended

Address

Saint Charles Health System

Bend, Oregon, 97701

Clackamas Radiation Oncology Center, Clackamas, Oregon

Status

Suspended

Address

Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015

Clackamas, Oregon

Status

Recruiting

Address

Providence Cancer Institute Clackamas Clinic

Clackamas, Oregon, 97015

Site Contact

Site Public Contact

CanRsrchStudies@providence.org

503-215-2614

Bay Area Hospital, Coos Bay, Oregon

Status

Suspended

Address

Bay Area Hospital

Coos Bay, Oregon, 97420

Providence Newberg Medical Center, Newberg, Oregon

Status

Recruiting

Address

Providence Newberg Medical Center

Newberg, Oregon, 97132

Site Contact

Site Public Contact

CanRsrchStudies@providence.org

503-215-2614

Oregon City, Oregon

Status

Recruiting

Address

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045

Site Contact

Site Public Contact

CanRsrchStudies@providence.org

503-215-2614

Providence Portland Medical Center, Portland, Oregon

Status

Recruiting

Address

Providence Portland Medical Center

Portland, Oregon, 97213

Site Contact

Site Public Contact

CanRsrchStudies@providence.org

503-215-2614

Providence Saint Vincent Medical Center, Portland, Oregon

Status

Recruiting

Address

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Site Contact

Site Public Contact

CanRsrchStudies@providence.org

503-215-2614

Oregon Health and Science University, Portland, Oregon

Status

Not yet recruiting

Address

Oregon Health and Science University

Portland, Oregon, 97239

Site Contact

Site Public Contact

trials@ohsu.edu

503-494-1080

Saint Charles Health System-Redmond, Redmond, Oregon

Status

Suspended

Address

Saint Charles Health System-Redmond

Redmond, Oregon, 97756

Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania

Status

Recruiting

Address

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

Site Contact

Site Public Contact

Morgan_M.Horton@lvhn.org

610-402-9543

Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania

Status

Recruiting

Address

Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017

Site Contact

Site Public Contact

Morgan_M.Horton@lvhn.org

610-402-9543

Pocono Medical Center, East Stroudsburg, Pennsylvania

Status

Suspended

Address

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301

Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania

Status

Suspended

Address

Lehigh Valley Hospital-Hazleton

Hazleton, Pennsylvania, 18201

Farmington Health Center, Farmington, Utah

Status

Recruiting

Address

Farmington Health Center

Farmington, Utah, 84025

Site Contact

Site Public Contact

cancerinfo@hci.utah.edu

888-424-2100

Salt Lake City, Utah

Status

Recruiting

Address

University of Utah Sugarhouse Health Center

Salt Lake City, Utah, 84106

Site Contact

Site Public Contact

cancerinfo@hci.utah.edu

888-424-2100

Salt Lake City, Utah

Status

Recruiting

Address

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

Site Contact

Site Public Contact

cancerinfo@hci.utah.edu

888-424-2100

Aberdeen, Washington

Status

Suspended

Address

Providence Regional Cancer System-Aberdeen

Aberdeen, Washington, 98520

PeaceHealth Saint Joseph Medical Center, Bellingham, Washington

Status

Suspended

Address

PeaceHealth Saint Joseph Medical Center

Bellingham, Washington, 98225

Centralia, Washington

Status

Suspended

Address

Providence Regional Cancer System-Centralia

Centralia, Washington, 98531

Swedish Cancer Institute-Edmonds, Edmonds, Washington

Status

Suspended

Address

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Providence Regional Cancer Partnership, Everett, Washington

Status

Suspended

Address

Providence Regional Cancer Partnership

Everett, Washington, 98201

Swedish Cancer Institute-Issaquah, Issaquah, Washington

Status

Suspended

Address

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Kadlec Clinic Hematology and Oncology, Kennewick, Washington

Status

Recruiting

Address

Kadlec Clinic Hematology and Oncology

Kennewick, Washington, 99336

Site Contact

Site Public Contact

research@kadlecmed.org

509-783-4637

Providence Regional Cancer System-Lacey, Lacey, Washington

Status

Suspended

Address

Providence Regional Cancer System-Lacey

Lacey, Washington, 98503

PeaceHealth Saint John Medical Center, Longview, Washington

Status

Suspended

Address

PeaceHealth Saint John Medical Center

Longview, Washington, 98632

Pacific Gynecology Specialists, Seattle, Washington

Status

Suspended

Address

Pacific Gynecology Specialists

Seattle, Washington, 98104

Swedish Medical Center-Ballard Campus, Seattle, Washington

Status

Suspended

Address

Swedish Medical Center-Ballard Campus

Seattle, Washington, 98107

Swedish Medical Center-Cherry Hill, Seattle, Washington

Status

Suspended

Address

Swedish Medical Center-Cherry Hill

Seattle, Washington, 98122-5711

Swedish Medical Center-First Hill, Seattle, Washington

Status

Suspended

Address

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Sedro-Woolley, Washington

Status

Suspended

Address

PeaceHealth United General Medical Center

Sedro-Woolley, Washington, 98284

Shelton, Washington

Status

Suspended

Address

Providence Regional Cancer System-Shelton

Shelton, Washington, 98584

PeaceHealth Southwest Medical Center, Vancouver, Washington

Status

Recruiting

Address

PeaceHealth Southwest Medical Center

Vancouver, Washington, 98664

Site Contact

Site Public Contact

kmakin-bond@peacehealth.org

360-514-3940

Walla Walla, Washington

Status

Suspended

Address

Providence Saint Mary Regional Cancer Center

Walla Walla, Washington, 99362

Providence Regional Cancer System-Yelm, Yelm, Washington

Status

Suspended

Address

Providence Regional Cancer System-Yelm

Yelm, Washington, 98597

Cancer Center of Western Wisconsin, New Richmond, Wisconsin

Status

Suspended

Address

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

Powered By

Stay Informed & Connected